Introduction
============

Vitiligo is a dermatogic disease ([@b1-etm-0-0-6937]), whose pathogenesis is currently only slightly understood. Vitiligo is a melanocyte-specific damage disease, and many scholars have speculated that the occurrence of vitiligo is very likely to be caused by the autoimmune dysfunction of patients ([@b2-etm-0-0-6937],[@b3-etm-0-0-6937]). There is a variety of cytokines in the body which can form a very complex immune regulatory network through the mutual feedback and regulatory effect of synthesis and secretion, and the mutual influence, regulatory effect and biological effect of the expression of cytokine receptors ([@b4-etm-0-0-6937],[@b5-etm-0-0-6937]). Abdellatif *et al* ([@b6-etm-0-0-6937]) have proposed that the proliferation activity of T cells in the peripheral blood of patients with vitiligo is abnormal, and the T cell-mediated normal melanocyte antigen response plays an important role in the occurrence of vitiligo. In the present study, in order to further investigate the pathogenesis of vitiligo, the levels of soluble intercellular adhesion molecule-1 (sICAM-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) in the skin tissue fluid and the levels of interleukin (IL)-6, IL-17 and tumor necrosis factor-α (TNF-α) in the blood of patients with vitiligo were detected, and their correlations with the course of disease and skin lesion area of patients were explored.

Materials and methods
=====================

### General data

A total of 120 patients diagnosed with vitiligo and treated in Daqing Long Nan Hospital (Daqing, China) from March 2014 to March 2016 were selected, according to the diagnostic and staging criteria of vitiligo ([@b7-etm-0-0-6937],[@b8-etm-0-0-6937]), including 66 male patients and 54 female patients, 15--72 years of age, with the course of disease being 3 months to 15 years. Among them, 60 patients of 14--70 years of age, with the course of disease being 2 months to 14 years, were in the progressive stage; and 60 patients of 16--72 years of age, with the course of disease being 4 months to 16 years, were in the stable stage. The skin lesion areas of all patients enrolled were recorded and presented as percentage. Another 80 healthy volunteers receiving physical examination in Daqing Long Nan Hospital during the same period were selected as control group, including 44 males and 36 females, 18--70 years of age. The age and sex of all subjects in vitiligo and control group were comparable (P\>0.05).

Exclusion criteria: patients with severe cardiovascular or cerebrovascular diseases, liver or kidney disease, infection, tumor or other autoimmune diseases, or patients receiving any immunotherapy within 1 month before detection.

The study was approved by the Ethics Committee of Daqing Long Nan Hospital and informed consents were signed by the patients or the guardians.

Methods
-------

### Collection of skin tissue fluid

The blebs at white and non-white spots of patients with vitiligo were sucked via negative pressure suction using a negative pressure suction instrument (Jiangsu Keling Medical Appliances Co., Ltd., Jiangsu, China). More visible blebs could be seen after 2 h. The bleb fluid at white and non-white spots was collected using a sterile disposable syringe, and it was stored in a refrigerator at −20°C to be detected.

### Collection of serum

A total of 5 ml fasting blood was collected into anticoagulant tubes from vitiligo patients and healthy volunteers receiving physical examination in the morning. The samples were placed in the refrigerator at −4°C for 2 h. The serum of the two groups was collected from the blood via centrifugation at 1,300 × g for 5 min at 4°C, labeled and placed in the refrigerator at −20°C in order to be detected.

### Detection of sICAM-1 levels in the skin tissue fluid via radioimmunoassay (RIA) kit

The RIA kit was purchased from Shanghai Kemin Biotechnology Co., Ltd. (Shanghai, China). DFM-96 RIA γ counter was used as the measuring instrument and the detection was performed strictly according to the manufacturer\'s instructions of the RIA kit.

### Detection of serum IL-6, IL-17, TNF-α and GM-CSF levels via enzyme-linked immunosorbent assay (ELISA) kit

IL-6, IL-17 and TNF-α ELISA kits were purchased from Shanghai Jingkang Biological Engineering Co., Ltd. (Shanghai, China), and the GM-CSF ELISA kit was purchased from Shanghai Beinuo Biotech Co., Ltd. (Shanghai, China). Bio-Rad 550 full-automatic enzyme-labeling counter (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used as the measuring instrument, and the detection was performed strictly according to the manufacturer\'s instructions of the ELISA kit.

### Statistical analysis

Statistical Product and Service Solutions (SPSS) 19.0 software (IBM Corp., Armonk, NY, USA) was used for the statistical analysis of the data. Measurement data are presented as mean ± standard deviation. t-test was used for the intergroup comparison. ANOVA was used for comparison between multiple groups and the post hoc test was LSD test. The Pearson\'s correlation test was utilized to analyze correlation. α=0.05 was used as the inspection level.

Results
=======

### Expression of IL-6, IL-17 and TNF-α in the blood of patients of both groups

The expression levels of IL-6, IL-17 and TNF-α in the blood of patients in the healthy control group were significantly lower than those in the vitiligo group, and the differences were statistically significant (P\<0.05) ([Table I](#tI-etm-0-0-6937){ref-type="table"}).

### IL-6, IL-17 and TNF-α in the blood of patients with vitiligo in different stages

There were no significant differences in the expression levels of IL-6, IL-17 and TNF-α in the blood of patients of the healthy control group and the patients at the stable stage; but the levels were significantly lower than those in the blood of patients in progressive stage, and the differences were statistically significant (P\<0.05) ([Table II](#tII-etm-0-0-6937){ref-type="table"}).

### Levels of sICAM-1 and GM-CSF in the skin tissue fluid of patients with vitiligo

The levels of sICAM-1 and GM-CSF in the skin tissue fluid at white spots of patients with vitiligo vulgaris were significantly higher than those in the skin tissue fluid at non-white spots, and the differences were statistically significant (P\<0.05). There were no significant changes in the levels of sICAM-1 and GM-CSF in the skin tissue fluid at white and non-white spots of patients with segmental vitiligo, and the differences were not statistically significant (P\>0.05) ([Table III](#tIII-etm-0-0-6937){ref-type="table"}).

### Correlation of sICAM-1 levels in the skin tissue fluid with the levels of IL-6, IL-17 and TNF-α in the blood

Pearson\'s correlation test showed that the sICAM-1 levels in the skin tissue fluid were significantly positive correlated with the levels of IL-6, IL-17 and TNF-α in the blood (correlation coefficient r=0.5141, 0.5423 and 0.5657, P\<0.05) ([Fig. 1](#f1-etm-0-0-6937){ref-type="fig"}).

### Correlation of sICAM-1 and IL-6 levels with the course of disease of patients

Pearson\'s correlation test showed that the levels of sICAM-1 in the skin tissue fluid and IL-6 in the blood of patients with vitiligo were negatively correlated with the course of disease (r=−0.5999 and −0.5013, P\<0.05 and P=0.0002) ([Fig. 2](#f2-etm-0-0-6937){ref-type="fig"}).

### Correlation of the factor levels with the skin lesion area of patients

Pearson\'s correlation test showed that the levels of sICAM-1 in the skin tissue fluid and IL-6 and IL-17 in the blood of patients with vitiligo were positively correlated with the skin lesion area of patients (r=0.3772, 0.4353 and 0.3668, P=0.0069, 0.0016 and 0.0088) ([Fig. 3](#f3-etm-0-0-6937){ref-type="fig"}).

Discussion
==========

sICAM-1 is a shedding cycle mode of ICAM-1 which mainly mediates the inflammatory response among cells, as a kind of adhesion molecule ([@b9-etm-0-0-6937]). Aydıngöz *et al* ([@b10-etm-0-0-6937]) have found that there is a significant positive correlation between ICAM-1 and sICAM-1. Camara-Lemarroy and Salas-Alanis ([@b11-etm-0-0-6937]) have shown that the expression level of sICAM-1 in the blood of patients with progressive vitiligo is higher, and it is speculated that sICAM-1 can be used as one of the indexes of vitiligo activity. Farhan *et al* ([@b12-etm-0-0-6937]) have found that lymphocyte relocation can be seen in the skin lesion, and this relocation process is synchronized with the destruction of melanocytes. Further studies have shown that ICAM-1 can promote the adhesion process *in vivo*, leading to the destruction of melanocytes. IL-17 *in vivo* can effectively promote the synthesis of interferon and TNF, further inducing the ICAM-1 expression. In this study, the levels of sICAM-1 in the skin tissue fluid at white spots of patients with vitiligo vulgaris were found to be significantly higher than that in the skin tissue fluid at non-white spots, but there were no significant changes in the levels of sICAM-1 in the skin tissue fluid at white and non-white spots of patients with segmental vitiligo, suggesting that depigmentation of skin in patients with vitiligo vulgaris is correlated with sICAM-1. The levels of sICAM-1 showed significant positive correlations with the levels of IL-6, IL-17 and TNF-α, so it is speculated that with the increase of sICAM-1 level in the tissue fluid, the secretion of IL-6, IL-17 and TNF-α is promoted via cell adhesion and receptor binding, eventually leading to increased expression levels in the blood.

GM-CSF, as the mitogen of melanocytes, can provide endogenous promoters for the growth of melanocytes ([@b13-etm-0-0-6937],[@b14-etm-0-0-6937]). Zhou *et al* ([@b15-etm-0-0-6937]) have shown via animal experiments that GM-CSF can induce autoimmune gastritis in rats. However, there have been no reports on its correlation with human vitiligo so far. In this study, the levels of GM-CSF in the skin tissue fluid at white spots of patients with vitiligo vulgaris were found to be significantly higher than that in the skin tissue fluid at non-white spots, but there were no significant changes in the levels of GM-CSF in the skin tissue fluid at white and non-white spots of patients with segmental vitiligo, and the levels of GM-CSF had no significant correlations with other factors selected in this study.

IL-6, as a kind of stimulating factor, shows a variety of biological functions *in vivo* ([@b16-etm-0-0-6937]). Miniati *et al* ([@b17-etm-0-0-6937]) have found that the expression of serum IL-6 in patients with vitiligo is significantly higher than that in normal subjects. It is speculated that the increase of IL-6 levels may be due to the destruction of cellular network in patients with vitiligo. When cells secrete IL-6 continuously, IL-6 can bind to the receptor and further stimulate the proliferation of cells, thereby leading to local skin damage. It was also found in this study that the expression of serum IL-6 in patients with vitiligo is increased, the expression level of sICAM-1 is significantly related to IL-6, and the larger the skin lesion area of patients is, the higher the expression of IL-6 will be. Moreover, the longer the course of disease is, the lower the level of IL-6 will be, presumably because the disease gradually becomes stable, and the IL-6 level is decreased with the extension of the course of disease.

IL-17 is mainly produced by T cells ([@b18-etm-0-0-6937]). In this study, it was found that the expression of serum IL-17 in patients with vitiligo is increased, and it is positively correlated with the skin lesion area. Some scholars speculate that IL-17 in the body may change the local microenvironment of patients, leading to melanocyte damage and vitiligo. TNF-α is a kind of cytokine with dual effects, which can be involved in the immune damage of the body ([@b19-etm-0-0-6937],[@b20-etm-0-0-6937]). It was found in this study that the level of serum TNF-α in patients with vitiligo is increased, presumably because TNF-α causes immune suppression in the body, so lymphocytes cannot exert normal immune response.

In conclusion, the levels of sICAM-1 and GM-CSF in the skin tissue fluid, and the expression of IL-6, IL-17 and TNF-α in the blood of patients with vitiligo are abnormal, but there are no significant correlations of GM-CSF with the expression of other factors, and the expression of sICAM-1 and IL-6 are correlated with the course of disease and skin lesion area of patients.
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###### 

Expression of IL-6, IL-17 and TNF-α in the blood of patients of both groups (mean ± standard deviation).

  Group             n     IL-6 (ng/l)                                                  IL-17 (g/l)                                                TNF-α (µg/l)
  ----------------- ----- ------------------------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------
  Healthy control   80    104.29±37.61                                                 9.74±3.48                                                  0.88±0.25
  Vitiligo          120   188.47±58.42^[a](#tfn1-etm-0-0-6937){ref-type="table-fn"}^   14.29±4.31^[a](#tfn1-etm-0-0-6937){ref-type="table-fn"}^   2.04±0.73^[a](#tfn1-etm-0-0-6937){ref-type="table-fn"}^

P\<0.05 vs. healthy control group. IL, interleukin; TNF-α, tumor necrosis factor-α.

###### 

Expression of IL-6, IL-17 and TNF-α in the blood of patients with vitiligo at different stages (mean ± standard deviation).

  Group                           n    IL-6 (ng/l)                                                  IL-17 (g/l)                                                TNF-α (µg/l)
  ------------------------------- ---- ------------------------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------
  Healthy controls                80   104.29±37.61^[a](#tfn2-etm-0-0-6937){ref-type="table-fn"}^   9.74±3.48^[a](#tfn2-etm-0-0-6937){ref-type="table-fn"}^    0.88±0.25^[a](#tfn2-etm-0-0-6937){ref-type="table-fn"}^
  Patients in progressive stage   60   238.42±55.29                                                 17.46±4.99                                                 2.52±0.96
  Patients in stable stage        60   112.49±40.05^[a](#tfn2-etm-0-0-6937){ref-type="table-fn"}^   10.61±4.16^[a](#tfn2-etm-0-0-6937){ref-type="table-fn"}^   1.16±0.44^[a](#tfn2-etm-0-0-6937){ref-type="table-fn"}^

P\<0.05 vs. patients in the progressive stage. IL, interleukin; TNF-α, tumor necrosis factor-α.

###### 

Levels of sICAM-1 and GM-CSF in the skin tissue fluid of patients with vitiligo (mean ± standard deviation).

  Group                n    sICAM-1 (ng/ml)                                              GM-CSF (ng/ml)
  -------------------- ---- ------------------------------------------------------------ ---------------------------------------------------------
  Vitiligo vulgaris    88                                                                
    White spots        44   285.42±39.71                                                 0.57±0.08
    Non-white spots    44   164.27±31.38^[a](#tfn3-etm-0-0-6937){ref-type="table-fn"}^   0.24±0.05^[a](#tfn3-etm-0-0-6937){ref-type="table-fn"}^
  Segmental vitiligo   32                                                                
    White spots        16   151.49±41.36                                                 0.51±0.07
    Non-white spots    16   147.52±46.03^[b](#tfn4-etm-0-0-6937){ref-type="table-fn"}^   0.48±0.06^[b](#tfn4-etm-0-0-6937){ref-type="table-fn"}^

P\<0.05

P\>0.05 vs. white spots. sICAM-1, soluble intercellular adhesion molecule-1; GM-CSF, granulocyte-macrophage colony stimulating factor.
